Loading
Leads one of the largest breast medical oncology departments, and led the ribociclib trial in premenopausal women.
Debu Tripathy is Chair of the Department of Breast Medical Oncology at MD Anderson Cancer Center and editor-in-chief of the journal Cancer. A breast medical oncologist specialising in endocrine therapy and clinical trials, he was principal investigator of MONALEESA-7, the phase 3 trial of ribociclib plus endocrine therapy in premenopausal women with hormone-receptor-positive advanced breast cancer, and is a leader in HER2-directed and antibody-drug conjugate trials. His papers report the MONALEESA-7 trial in Lancet Oncology and its overall survival analysis in the New England Journal of Medicine. He leads one of the largest breast medical oncology departments, working on CDK4/6 and the oestrogen receptor.
| Title | Journal | Year |
|---|---|---|
| Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial | Lancet Oncology | 2018 |
| Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer | New England Journal of Medicine | 2019 |
Shares MD Anderson Cancer Center, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
Shares Ribociclib, CDK4/6, Estrogen receptor (ERα), Triple-negative breast cancer (TNBC).
Shares Ribociclib, CDK4/6, MD Anderson Cancer Center, HR-positive / HER2-negative breast cancer.
Shares CDK4/6, MD Anderson Cancer Center.
Shares CDK4/6, Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer.
Shares CDK4/6, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
Shares CDK4/6, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
Shares CDK4/6, Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer.